Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential
PURPOSE: Inhibitors of intestinal alpha-glucosidases are used therapeutically to treat type 2 diabetes mellitus. Bacteria such as Actinoplanes sp. naturally produce potent alpha-glucosidase inhibitor compounds, including the most widely available drug acarbose. It is not known whether lactic acid ba...
Gespeichert in:
| Veröffentlicht in: | European journal of nutrition 2014-10, Vol.53 (7), p.1465-1474 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1474 |
|---|---|
| container_issue | 7 |
| container_start_page | 1465 |
| container_title | European journal of nutrition |
| container_volume | 53 |
| creator | Panwar, Harsh Calderwood, Danielle Grant, Irene R Grover, Sunita Green, Brian D |
| description | PURPOSE: Inhibitors of intestinal alpha-glucosidases are used therapeutically to treat type 2 diabetes mellitus. Bacteria such as Actinoplanes sp. naturally produce potent alpha-glucosidase inhibitor compounds, including the most widely available drug acarbose. It is not known whether lactic acid bacteria (LAB) colonising the human gut possess inhibitory potential against glucosidases. Hence, the study was undertaken to screen LABs having inherent alpha- and beta-glucosidase inhibitory potential. METHODS: This study isolated, screened, identified and extracted Lactobacillus strains (Lb1–15) from human infant faecal samples determining their inhibitory activity against intestinal maltase, sucrase, lactase and amylase. Lactobacillus reference strains (Ref1–7), a Gram positive control (Ctrl1) and two Gram negative controls (Ctrl2–3), were also analysed to compare activity. RESULTS: Faecal isolates were identified by DNA sequencing, with the majority identified as unique strains of Lactobacillus plantarum. Some strains (L. plantarum, L. fermentum, L. casei and L. rhamnosus) had potent and broad spectrum inhibitory activities (up to 89 %; p |
| doi_str_mv | 10.1007/s00394-013-0649-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1618149930</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1618149930</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-f9ab6711ebac04f8a511f80d158cc01ae9ff20f657bd5ba33112d0781c861f533</originalsourceid><addsrcrecordid>eNqFksFu1DAQhiMEoqXwAFzAEqrEJeCx48Q5oooC0kocoOdo4tipK2-y2A5Sn4jXZNIsBXEA-TCW55t_xv5dFM-BvwHOm7eJc9lWJQdZ8rpqy_ZBcQqVrMtagHp4v-fNSfEkpRvOuZA1PC5ORFUBLXFa_NihyXOPxoewJJZyRD8l5tMcMNuBuTjvmZ8cTpk5tMYmdphTsmmN2dKpn6597_McbxlJ-e8-02ZcVdZctin7CQPDcLjGkuE0sN5mLMewmDn5AUmLpWUc78CRgOzLwSNB3hx7eAxPi0cOQ7LPjvGsuLp8__XiY7n7_OHTxbtdaZRoc-la7OsGwNKNeOU0KgCn-QBKG8MBbeuc4K5WTT-oHqUEEANvNBhdg1NSnhWvN91DnL8tNFO398nYEHCy85I6qEFD1baS_x9VdQ1cc7mqvvoLvZmXSM9yR1VKNVIIomCjTKQnjtZ1h-j3GG874N1qeLcZ3pHh3Wp411LNi6Py0u_tcF_xy2ECzo8AJoPBRZyMT785rTU1B-LExiVKTaONf4z4j-4vtyKHc4djJOGrL4KDoq-midbyJ0v4z4Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1564557322</pqid></control><display><type>article</type><title>Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Panwar, Harsh ; Calderwood, Danielle ; Grant, Irene R ; Grover, Sunita ; Green, Brian D</creator><creatorcontrib>Panwar, Harsh ; Calderwood, Danielle ; Grant, Irene R ; Grover, Sunita ; Green, Brian D</creatorcontrib><description>PURPOSE: Inhibitors of intestinal alpha-glucosidases are used therapeutically to treat type 2 diabetes mellitus. Bacteria such as Actinoplanes sp. naturally produce potent alpha-glucosidase inhibitor compounds, including the most widely available drug acarbose. It is not known whether lactic acid bacteria (LAB) colonising the human gut possess inhibitory potential against glucosidases. Hence, the study was undertaken to screen LABs having inherent alpha- and beta-glucosidase inhibitory potential. METHODS: This study isolated, screened, identified and extracted Lactobacillus strains (Lb1–15) from human infant faecal samples determining their inhibitory activity against intestinal maltase, sucrase, lactase and amylase. Lactobacillus reference strains (Ref1–7), a Gram positive control (Ctrl1) and two Gram negative controls (Ctrl2–3), were also analysed to compare activity. RESULTS: Faecal isolates were identified by DNA sequencing, with the majority identified as unique strains of Lactobacillus plantarum. Some strains (L. plantarum, L. fermentum, L. casei and L. rhamnosus) had potent and broad spectrum inhibitory activities (up to 89 %; p < 0.001; 500 mg/ml wet weight) comparable to acarbose (up to 88 %; p < 0.001; 30 mg/ml). Inhibitory activity was concentration-dependent and was freely available in the supernatant, and was not present in other bacterial genera (Bifidobacterium bifidum and Escherichia coli or Salmonella typhimurium). Interestingly, the potency and spectrum of inhibitory activity across strains of a single species (L. plantarum) differed substantially. Some Lactobacillus extracts had broader spectrum activities than acarbose, effectively inhibiting beta-glucosidase activity (lactase) as well as alpha-glucosidase activities (maltase, sucrase and amylase). Anti-diabetic potential was indicated by the fact that oral gavage with a L. rhamnosus extract (1 g/kg) was able to reduce glucose excursions (Area under curve; 22 %; p < 0.05) in rats during a carbohydrate challenge (starch; 2 g/kg). CONCLUSION: These results definitively demonstrate that Lactobacillus strains present in the human gut have alpha- and beta-glucosidase inhibitory activities and can reduce blood glucose responses in vivo. Although the potential use of LAB such as Lactobacillus as a dietary supplement, medicinal food or biotherapeutic for diabetes is uncertain, such an approach might offer advantages over drug therapies in terms of broader spectrum activities and fewer unpleasant side effects. Further characterisation of this bioactivity is warranted, and chronic studies should be undertaken in appropriate animal models or diabetic subjects.</description><identifier>ISSN: 1436-6207</identifier><identifier>EISSN: 1436-6215</identifier><identifier>DOI: 10.1007/s00394-013-0649-9</identifier><identifier>PMID: 24414142</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject><![CDATA[acarbose ; Acarbose - metabolism ; Actinoplanes ; adverse effects ; alpha-glucosidase ; alpha-Glucosidases - metabolism ; Amylases - antagonists & inhibitors ; animal models ; Animals ; beta-galactosidase ; beta-glucosidase ; beta-Glucosidase - antagonists & inhibitors ; Bifidobacterium bifidum ; Biological and medical sciences ; blood glucose ; Blood Glucose - metabolism ; Chemistry ; Chemistry and Materials Science ; Diabetes Mellitus, Type 2 - therapy ; dietary supplements ; digestive system ; DNA, Bacterial - isolation & purification ; drugs ; Enzyme Inhibitors - pharmacology ; Escherichia coli ; feces ; Feces - microbiology ; Feeding. Feeding behavior ; functional foods ; Fundamental and applied biological sciences. Psychology ; glucose ; Glycoside Hydrolase Inhibitors - pharmacology ; Humans ; Hypoglycemic Agents - pharmacology ; Infant ; Intestines - enzymology ; Intestines - microbiology ; Lactase - antagonists & inhibitors ; lactic acid bacteria ; Lactobacillus ; Lactobacillus - classification ; Lactobacillus - isolation & purification ; Lactobacillus plantarum ; noninsulin-dependent diabetes mellitus ; Nutrition ; Original Contribution ; Probiotics ; Rats ; Rats, Sprague-Dawley ; Salmonella typhimurium ; sequence analysis ; Sequence Analysis, DNA ; starch ; Sucrase - antagonists & inhibitors ; sucrose alpha-glucosidase ; Vertebrates: anatomy and physiology, studies on body, several organs or systems]]></subject><ispartof>European journal of nutrition, 2014-10, Vol.53 (7), p.1465-1474</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-f9ab6711ebac04f8a511f80d158cc01ae9ff20f657bd5ba33112d0781c861f533</citedby><cites>FETCH-LOGICAL-c529t-f9ab6711ebac04f8a511f80d158cc01ae9ff20f657bd5ba33112d0781c861f533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00394-013-0649-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00394-013-0649-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28887321$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24414142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Panwar, Harsh</creatorcontrib><creatorcontrib>Calderwood, Danielle</creatorcontrib><creatorcontrib>Grant, Irene R</creatorcontrib><creatorcontrib>Grover, Sunita</creatorcontrib><creatorcontrib>Green, Brian D</creatorcontrib><title>Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential</title><title>European journal of nutrition</title><addtitle>Eur J Nutr</addtitle><addtitle>Eur J Nutr</addtitle><description>PURPOSE: Inhibitors of intestinal alpha-glucosidases are used therapeutically to treat type 2 diabetes mellitus. Bacteria such as Actinoplanes sp. naturally produce potent alpha-glucosidase inhibitor compounds, including the most widely available drug acarbose. It is not known whether lactic acid bacteria (LAB) colonising the human gut possess inhibitory potential against glucosidases. Hence, the study was undertaken to screen LABs having inherent alpha- and beta-glucosidase inhibitory potential. METHODS: This study isolated, screened, identified and extracted Lactobacillus strains (Lb1–15) from human infant faecal samples determining their inhibitory activity against intestinal maltase, sucrase, lactase and amylase. Lactobacillus reference strains (Ref1–7), a Gram positive control (Ctrl1) and two Gram negative controls (Ctrl2–3), were also analysed to compare activity. RESULTS: Faecal isolates were identified by DNA sequencing, with the majority identified as unique strains of Lactobacillus plantarum. Some strains (L. plantarum, L. fermentum, L. casei and L. rhamnosus) had potent and broad spectrum inhibitory activities (up to 89 %; p < 0.001; 500 mg/ml wet weight) comparable to acarbose (up to 88 %; p < 0.001; 30 mg/ml). Inhibitory activity was concentration-dependent and was freely available in the supernatant, and was not present in other bacterial genera (Bifidobacterium bifidum and Escherichia coli or Salmonella typhimurium). Interestingly, the potency and spectrum of inhibitory activity across strains of a single species (L. plantarum) differed substantially. Some Lactobacillus extracts had broader spectrum activities than acarbose, effectively inhibiting beta-glucosidase activity (lactase) as well as alpha-glucosidase activities (maltase, sucrase and amylase). Anti-diabetic potential was indicated by the fact that oral gavage with a L. rhamnosus extract (1 g/kg) was able to reduce glucose excursions (Area under curve; 22 %; p < 0.05) in rats during a carbohydrate challenge (starch; 2 g/kg). CONCLUSION: These results definitively demonstrate that Lactobacillus strains present in the human gut have alpha- and beta-glucosidase inhibitory activities and can reduce blood glucose responses in vivo. Although the potential use of LAB such as Lactobacillus as a dietary supplement, medicinal food or biotherapeutic for diabetes is uncertain, such an approach might offer advantages over drug therapies in terms of broader spectrum activities and fewer unpleasant side effects. Further characterisation of this bioactivity is warranted, and chronic studies should be undertaken in appropriate animal models or diabetic subjects.</description><subject>acarbose</subject><subject>Acarbose - metabolism</subject><subject>Actinoplanes</subject><subject>adverse effects</subject><subject>alpha-glucosidase</subject><subject>alpha-Glucosidases - metabolism</subject><subject>Amylases - antagonists & inhibitors</subject><subject>animal models</subject><subject>Animals</subject><subject>beta-galactosidase</subject><subject>beta-glucosidase</subject><subject>beta-Glucosidase - antagonists & inhibitors</subject><subject>Bifidobacterium bifidum</subject><subject>Biological and medical sciences</subject><subject>blood glucose</subject><subject>Blood Glucose - metabolism</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Diabetes Mellitus, Type 2 - therapy</subject><subject>dietary supplements</subject><subject>digestive system</subject><subject>DNA, Bacterial - isolation & purification</subject><subject>drugs</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Escherichia coli</subject><subject>feces</subject><subject>Feces - microbiology</subject><subject>Feeding. Feeding behavior</subject><subject>functional foods</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>glucose</subject><subject>Glycoside Hydrolase Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Infant</subject><subject>Intestines - enzymology</subject><subject>Intestines - microbiology</subject><subject>Lactase - antagonists & inhibitors</subject><subject>lactic acid bacteria</subject><subject>Lactobacillus</subject><subject>Lactobacillus - classification</subject><subject>Lactobacillus - isolation & purification</subject><subject>Lactobacillus plantarum</subject><subject>noninsulin-dependent diabetes mellitus</subject><subject>Nutrition</subject><subject>Original Contribution</subject><subject>Probiotics</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Salmonella typhimurium</subject><subject>sequence analysis</subject><subject>Sequence Analysis, DNA</subject><subject>starch</subject><subject>Sucrase - antagonists & inhibitors</subject><subject>sucrose alpha-glucosidase</subject><subject>Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><issn>1436-6207</issn><issn>1436-6215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqFksFu1DAQhiMEoqXwAFzAEqrEJeCx48Q5oooC0kocoOdo4tipK2-y2A5Sn4jXZNIsBXEA-TCW55t_xv5dFM-BvwHOm7eJc9lWJQdZ8rpqy_ZBcQqVrMtagHp4v-fNSfEkpRvOuZA1PC5ORFUBLXFa_NihyXOPxoewJJZyRD8l5tMcMNuBuTjvmZ8cTpk5tMYmdphTsmmN2dKpn6597_McbxlJ-e8-02ZcVdZctin7CQPDcLjGkuE0sN5mLMewmDn5AUmLpWUc78CRgOzLwSNB3hx7eAxPi0cOQ7LPjvGsuLp8__XiY7n7_OHTxbtdaZRoc-la7OsGwNKNeOU0KgCn-QBKG8MBbeuc4K5WTT-oHqUEEANvNBhdg1NSnhWvN91DnL8tNFO398nYEHCy85I6qEFD1baS_x9VdQ1cc7mqvvoLvZmXSM9yR1VKNVIIomCjTKQnjtZ1h-j3GG874N1qeLcZ3pHh3Wp411LNi6Py0u_tcF_xy2ECzo8AJoPBRZyMT785rTU1B-LExiVKTaONf4z4j-4vtyKHc4djJOGrL4KDoq-midbyJ0v4z4Y</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Panwar, Harsh</creator><creator>Calderwood, Danielle</creator><creator>Grant, Irene R</creator><creator>Grover, Sunita</creator><creator>Green, Brian D</creator><general>Springer-Verlag</general><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RQ</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20141001</creationdate><title>Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential</title><author>Panwar, Harsh ; Calderwood, Danielle ; Grant, Irene R ; Grover, Sunita ; Green, Brian D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-f9ab6711ebac04f8a511f80d158cc01ae9ff20f657bd5ba33112d0781c861f533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>acarbose</topic><topic>Acarbose - metabolism</topic><topic>Actinoplanes</topic><topic>adverse effects</topic><topic>alpha-glucosidase</topic><topic>alpha-Glucosidases - metabolism</topic><topic>Amylases - antagonists & inhibitors</topic><topic>animal models</topic><topic>Animals</topic><topic>beta-galactosidase</topic><topic>beta-glucosidase</topic><topic>beta-Glucosidase - antagonists & inhibitors</topic><topic>Bifidobacterium bifidum</topic><topic>Biological and medical sciences</topic><topic>blood glucose</topic><topic>Blood Glucose - metabolism</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Diabetes Mellitus, Type 2 - therapy</topic><topic>dietary supplements</topic><topic>digestive system</topic><topic>DNA, Bacterial - isolation & purification</topic><topic>drugs</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Escherichia coli</topic><topic>feces</topic><topic>Feces - microbiology</topic><topic>Feeding. Feeding behavior</topic><topic>functional foods</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>glucose</topic><topic>Glycoside Hydrolase Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Infant</topic><topic>Intestines - enzymology</topic><topic>Intestines - microbiology</topic><topic>Lactase - antagonists & inhibitors</topic><topic>lactic acid bacteria</topic><topic>Lactobacillus</topic><topic>Lactobacillus - classification</topic><topic>Lactobacillus - isolation & purification</topic><topic>Lactobacillus plantarum</topic><topic>noninsulin-dependent diabetes mellitus</topic><topic>Nutrition</topic><topic>Original Contribution</topic><topic>Probiotics</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Salmonella typhimurium</topic><topic>sequence analysis</topic><topic>Sequence Analysis, DNA</topic><topic>starch</topic><topic>Sucrase - antagonists & inhibitors</topic><topic>sucrose alpha-glucosidase</topic><topic>Vertebrates: anatomy and physiology, studies on body, several organs or systems</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Panwar, Harsh</creatorcontrib><creatorcontrib>Calderwood, Danielle</creatorcontrib><creatorcontrib>Grant, Irene R</creatorcontrib><creatorcontrib>Grover, Sunita</creatorcontrib><creatorcontrib>Green, Brian D</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Career & Technical Education Database</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>European journal of nutrition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Panwar, Harsh</au><au>Calderwood, Danielle</au><au>Grant, Irene R</au><au>Grover, Sunita</au><au>Green, Brian D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential</atitle><jtitle>European journal of nutrition</jtitle><stitle>Eur J Nutr</stitle><addtitle>Eur J Nutr</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>53</volume><issue>7</issue><spage>1465</spage><epage>1474</epage><pages>1465-1474</pages><issn>1436-6207</issn><eissn>1436-6215</eissn><abstract>PURPOSE: Inhibitors of intestinal alpha-glucosidases are used therapeutically to treat type 2 diabetes mellitus. Bacteria such as Actinoplanes sp. naturally produce potent alpha-glucosidase inhibitor compounds, including the most widely available drug acarbose. It is not known whether lactic acid bacteria (LAB) colonising the human gut possess inhibitory potential against glucosidases. Hence, the study was undertaken to screen LABs having inherent alpha- and beta-glucosidase inhibitory potential. METHODS: This study isolated, screened, identified and extracted Lactobacillus strains (Lb1–15) from human infant faecal samples determining their inhibitory activity against intestinal maltase, sucrase, lactase and amylase. Lactobacillus reference strains (Ref1–7), a Gram positive control (Ctrl1) and two Gram negative controls (Ctrl2–3), were also analysed to compare activity. RESULTS: Faecal isolates were identified by DNA sequencing, with the majority identified as unique strains of Lactobacillus plantarum. Some strains (L. plantarum, L. fermentum, L. casei and L. rhamnosus) had potent and broad spectrum inhibitory activities (up to 89 %; p < 0.001; 500 mg/ml wet weight) comparable to acarbose (up to 88 %; p < 0.001; 30 mg/ml). Inhibitory activity was concentration-dependent and was freely available in the supernatant, and was not present in other bacterial genera (Bifidobacterium bifidum and Escherichia coli or Salmonella typhimurium). Interestingly, the potency and spectrum of inhibitory activity across strains of a single species (L. plantarum) differed substantially. Some Lactobacillus extracts had broader spectrum activities than acarbose, effectively inhibiting beta-glucosidase activity (lactase) as well as alpha-glucosidase activities (maltase, sucrase and amylase). Anti-diabetic potential was indicated by the fact that oral gavage with a L. rhamnosus extract (1 g/kg) was able to reduce glucose excursions (Area under curve; 22 %; p < 0.05) in rats during a carbohydrate challenge (starch; 2 g/kg). CONCLUSION: These results definitively demonstrate that Lactobacillus strains present in the human gut have alpha- and beta-glucosidase inhibitory activities and can reduce blood glucose responses in vivo. Although the potential use of LAB such as Lactobacillus as a dietary supplement, medicinal food or biotherapeutic for diabetes is uncertain, such an approach might offer advantages over drug therapies in terms of broader spectrum activities and fewer unpleasant side effects. Further characterisation of this bioactivity is warranted, and chronic studies should be undertaken in appropriate animal models or diabetic subjects.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>24414142</pmid><doi>10.1007/s00394-013-0649-9</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1436-6207 |
| ispartof | European journal of nutrition, 2014-10, Vol.53 (7), p.1465-1474 |
| issn | 1436-6207 1436-6215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1618149930 |
| source | MEDLINE; SpringerLink Journals |
| subjects | acarbose Acarbose - metabolism Actinoplanes adverse effects alpha-glucosidase alpha-Glucosidases - metabolism Amylases - antagonists & inhibitors animal models Animals beta-galactosidase beta-glucosidase beta-Glucosidase - antagonists & inhibitors Bifidobacterium bifidum Biological and medical sciences blood glucose Blood Glucose - metabolism Chemistry Chemistry and Materials Science Diabetes Mellitus, Type 2 - therapy dietary supplements digestive system DNA, Bacterial - isolation & purification drugs Enzyme Inhibitors - pharmacology Escherichia coli feces Feces - microbiology Feeding. Feeding behavior functional foods Fundamental and applied biological sciences. Psychology glucose Glycoside Hydrolase Inhibitors - pharmacology Humans Hypoglycemic Agents - pharmacology Infant Intestines - enzymology Intestines - microbiology Lactase - antagonists & inhibitors lactic acid bacteria Lactobacillus Lactobacillus - classification Lactobacillus - isolation & purification Lactobacillus plantarum noninsulin-dependent diabetes mellitus Nutrition Original Contribution Probiotics Rats Rats, Sprague-Dawley Salmonella typhimurium sequence analysis Sequence Analysis, DNA starch Sucrase - antagonists & inhibitors sucrose alpha-glucosidase Vertebrates: anatomy and physiology, studies on body, several organs or systems |
| title | Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T00%3A59%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lactobacillus%20strains%20isolated%20from%20infant%20faeces%20possess%20potent%20inhibitory%20activity%20against%20intestinal%20alpha-%20and%20beta-glucosidases%20suggesting%20anti-diabetic%20potential&rft.jtitle=European%20journal%20of%20nutrition&rft.au=Panwar,%20Harsh&rft.date=2014-10-01&rft.volume=53&rft.issue=7&rft.spage=1465&rft.epage=1474&rft.pages=1465-1474&rft.issn=1436-6207&rft.eissn=1436-6215&rft_id=info:doi/10.1007/s00394-013-0649-9&rft_dat=%3Cproquest_cross%3E1618149930%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1564557322&rft_id=info:pmid/24414142&rfr_iscdi=true |